We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Orforglipronis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Orforglipron studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2023–2026 with a typical study size of 559 participants.
Based on 11 studies · 1 meta-analysis · 9 RCTs · 9,536 total participants
Confidence
HighBy outcome
Orforglipron has an evidence score of 5.5/10 — moderate evidence based on 11 indexed studies, including 1 meta-analysis. An investigational ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. Honest appraisal: the phase-2 data are strong and the first phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it is INVESTIGATIONAL and not yet approved as a general weight-loss medicine, has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), and the expected thyroid C-cell class warning and long-term outcomes are unsettled. It is NOT a dietary supplement; listed here for reference only. Representative study: PMID 42116665.
The commonly studied dose of Orforglipron is INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 11 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Orforglipron (oral non-peptide GLP-1 receptor agonist)
An investigational ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. Honest appraisal: the phase-2 data are strong and the first phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it is INVESTIGATIONAL and not yet approved as a general weight-loss medicine, has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), and the expected thyroid C-cell class warning and long-term outcomes are unsettled. It is NOT a dietary supplement; listed here for reference only.
Phase-3 RCTs show strong, consistent glycemic and weight benefit, but it is an investigational, unapproved drug with very common GI side effects and no long-term outcome data.
Orforglipron (development code LY3502970) is an oral, NON-PEPTIDE small-molecule GLP-1 receptor agonist developed by Eli Lilly for type 2 diabetes and obesity.
Unlike semaglutide or liraglutide — which are peptides that must be injected (or, for oral semaglutide, co-formulated with an absorption enhancer and dosed on an empty stomach) — orforglipron is a true small molecule resistant to enzymatic degradation, so it can be taken as a simple once-daily tablet with no food or water restrictions.
That pill-not-injection convenience, plus the absence of cold-chain logistics, is the entire reason the drug matters: if approved it could make GLP-1 therapy far more scalable.
It is filed here under the 'peptide' category for catalogue consistency with the other GLP-1 agents, but it is mechanistically a small molecule (closer in that respect to MK-677, an oral non-peptide growth-hormone secretagogue, than to the injectable peptides).
Mechanistically it activates the GLP-1 receptor in the pancreas (glucose-dependent insulin secretion, suppressed glucagon), brain (appetite suppression/satiety) and gut (slowed gastric emptying) — the same downstream cascade as the injectable GLP-1 agonists.
The evidence as of mid-2026 is genuinely encouraging but still maturing.
Two 2023 phase-2 dose-response RCTs established the signal: in type 2 diabetes (Frias et al., Lancet 2023; n=383) orforglipron cut HbA1c up to ~2.1% (placebo-adjusted ~1.7%) and bodyweight up to ~10 kg, beating both placebo and injectable dulaglutide; in obesity without diabetes (Wharton et al., NEJM 2023; n=272) it produced ~9-15% weight loss by week 36 vs ~2% on placebo.
The phase-3 program has begun reporting: ACHIEVE-1 (NEJM 2025; n=559) showed HbA1c reductions to ~6.5-6.7% with up to ~7.6% weight loss in early type 2 diabetes; ATTAIN-1 (NEJM 2025; n=3127) showed ~11.2% mean weight loss at 72 weeks at the 36 mg dose in obesity without diabetes; ATTAIN-2 (Lancet 2026; n=1613) showed ~9.6% weight loss at 72 weeks in obesity WITH type 2 diabetes (a smaller effect, as expected when diabetes is present); ACHIEVE-2 (Lancet 2026) showed superiority to dapagliflozin on HbA1c; ACHIEVE-3 (Lancet 2026; n=1698) was the first head-to-head against oral semaglutide and showed orforglipron 12/36 mg non-inferior and statistically superior on HbA1c; ACHIEVE-5 (JAMA 2026) showed added benefit on top of insulin glargine; and ATTAIN-MAINTAIN (Nat Med 2026) showed it preserves weight loss after switching off injectable therapy.
The honest counterweight: orforglipron is INVESTIGATIONAL and not yet approved as a general anti-obesity medicine; gastrointestinal adverse events (nausea, vomiting, diarrhea) are very common and dose-dependent, requiring slow titration, and treatment discontinuation has run higher than placebo and, in at least one indirect comparison, higher than oral semaglutide; a network meta-analysis found dose-dependent GI events and pancreatic-enzyme elevations (without clinical pancreatitis) over 26 weeks; the GLP-1 class carries a thyroid C-cell (medullary carcinoma) boxed-warning concern that will be expected to apply; and long-term cardiovascular, safety, and durability data are not yet in.
It must never be obtained from grey-market/research-chemical channels — an unapproved investigational drug bought outside a clinical trial or pharmacy carries serious identity, dosing, and purity risks.
A small-molecule (non-peptide) agonist of the GLP-1 receptor, resistant to enzymatic degradation so it can be dosed orally — the single upstream target that drives all downstream metabolic effects, the same receptor the injectable GLP-1 peptides hit.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon, lowering blood glucose and HbA1c with low intrinsic hypoglycemia risk (no severe hypoglycemia in the trials).
Acts on central appetite-regulating circuits to increase satiety and reduce food intake — the primary driver of the weight loss seen across the phase-2 and ATTAIN phase-3 trials.
Delays gastric emptying, blunting post-meal glucose excursions and prolonging fullness — and the mechanism behind much of the dose-dependent nausea seen during titration.
How Orforglipron works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.
Loading: Dose is escalated gradually (e.g. starting 3 mg/day and stepping up over weeks toward 12-36 mg) specifically to reduce gastrointestinal side effects — done under trial/clinician supervision, never self-titrated.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral tablet (investigational) | Recommended |
A once-daily small-molecule pill is the entire point. Never source orforglipron from grey-market / research-chemical vendors — it is an unapproved investigational drug and off-trial product carries serious identity, dosing, and purity risks.
Minimum: 26 weeks
Optimal: 72 weeks
Cycling: Not required
Note: Once daily, any time of day, with or without food/water — the practical headline of the drug. Dose is titrated upward gradually under trial/clinician supervision; never self-escalate.
Dose-response data unavailable. The current published research for Orforglipron does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Large HbA1c reductions in type 2 diabetes across phase-2 (up to ~2.1%) and phase-3 (ACHIEVE-1 mean HbA1c to ~6.5-6.7%); superior to dapagliflozin (ACHIEVE-2) and additive to insulin glargine (ACHIEVE-5).
~9-15% weight loss in phase-2 obesity by 36 weeks; ATTAIN-1 phase-3 showed ~11.2% mean loss at 72 weeks at 36 mg (vs ~2.1% placebo). Generally somewhat below high-dose injectable peptides in indirect comparisons.
A true small-molecule tablet — no injection, no cold chain, no empty-stomach/water restrictions. The convenience and scalability are the main reason orforglipron is notable versus injectable GLP-1s.
Nausea, vomiting and diarrhea are the most frequent adverse events, dose-dependent and concentrated during titration. Discontinuation runs higher than placebo and, in one indirect comparison, higher than oral semaglutide.
Phase-3 reporting is underway but orforglipron is not an approved general weight-loss medicine; long-term cardiovascular and safety outcomes are not yet established.
Expected to be contraindicated — the GLP-1 class carries a thyroid C-cell tumor warning.
Use caution under specialist guidance, consistent with the GLP-1 class.
Contraindicated — weight loss and an investigational drug are not appropriate in pregnancy.
Not appropriate — it is an unapproved investigational drug; off-trial sourcing carries serious identity, dosing, and purity risks.
Combining a GLP-1 agonist with insulin or sulfonylureas raises hypoglycemia risk; in ACHIEVE-5 it was added to titrated insulin glargine under trial supervision with insulin adjustment. Orforglipron alone showed no severe hypoglycemia.
Delayed gastric emptying can change the absorption of co-administered oral drugs — a class consideration for any GLP-1 agonist.
Tip: Gradual dose titration; smaller meals; usually transient and concentrated during dose escalation
Tip: Slow titration, hydration, dietary adjustment; a common reason for discontinuation in the trials
Tip: Higher than placebo (and, in one indirect comparison, higher than oral semaglutide); slower titration may help
Tip: Dose-dependent enzyme rises were seen without clinical pancreatitis in a network meta-analysis; clinical significance unclear
Tip: No increased pancreatitis risk detected in the 26-week meta-analysis, but it remains a GLP-1-class caution; seek urgent care for severe persistent abdominal pain
Timing is flexible for Orforglipron — consistent daily use matters more than the time of day. Unlike oral semaglutide, orforglipron is a small molecule taken once daily with no food or water restrictions — a key practical advantage.
Orforglipron should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are nausea, vomiting / diarrhea, treatment discontinuation due to GI events. Use caution if any of these apply to you: Not an approved medicine — only appropriate within a clinical trial or, if/when approved, under a clinician; Expected: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — the GLP-1-class thyroid C-cell concern; History of pancreatitis (caution, consistent with the GLP-1 class).
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Do not combine with another GLP-1 agonist (semaglutide, liraglutide, dulaglutide, tirzepatide) — additive GI risk with no added benefit.